01 November 2004
Angiotensin II and its fragments (angiotensins III and IV) decrease the growth of DU-145 prostate cancer in vitro.
Hanna Ławnicka, Agnieszka M. Potocka, Alina Juzala, Marie Claude Fournie-Zaluski, Marek PawlikowskiMed Sci Monit 2004; 10(11): BR410-413 :: ID: 11805
Abstract
BACKGROUND: There is growing evidence that angiotensin II (AngII) and its smaller fragments 2-8 (AngIII) and 3-8 (AngIV) are involved in cell-growth control in the vascular smooth muscle and in some other tissues, including prostate. The aim of this paper was to investigate the effects of AngII and its fragments AngIII and AngIV on the growth of an androgen-independent human prostate cancer cell line in vitro. To see whether the conversion of Ang II into its shorter fragments plays a role in the action of the former, we used specific inhibitors of aminopeptidases: compound EC33 (inhibitor of aminopeptidase A), which blocks the conversion of AngII into AngIII, and compound PC 18 (inhibitor of aminopeptidase N), which blocks the conversion of AngIII into AngIV. MATERIAL/METHODS: Human prostate cancer DU-145 cells were exposed in culture to different concentrations of AngII, AngIII, and AngIV separately or jointly with the aminopeptidase inhibitors EC33 or PC18. To measure cell growth, the colorimetric method, based on the reduction of tetrazolium salt by viable cells, was applied. RESULTS: It was found that exposure of DU-145 cells in vitro to all the investigated angiotensins resulted in a moderate, concentration-dependent inhibition of cell growth. The joint exposure of DU-145 cells to AngII plus EC33, but not to AngII plus PC 18, abolished the effect of AngII. CONCLUSIONS: These findings suggest that angiotensin peptides (AngII as well as its smaller fragments) are involved in the negative control of prostate cancer cell growth.
Keywords: Angiotensin II - analogs & derivatives, Angiotensin II - therapeutic use, Angiotensin III - therapeutic use, Glutamyl Aminopeptidase - antagonists & inhibitors, Sulfonic Acids - pharmacology, Angiotensin II - therapeutic use, Angiotensin III - therapeutic use, Glutamyl Aminopeptidase - antagonists & inhibitors, Prostatic Neoplasms - drug therapy, Sulfonic Acids - pharmacology
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952